PL3068797T3 - Konstrukty wielowalentnego celowania w nowotwory - Google Patents

Konstrukty wielowalentnego celowania w nowotwory

Info

Publication number
PL3068797T3
PL3068797T3 PL14860292T PL14860292T PL3068797T3 PL 3068797 T3 PL3068797 T3 PL 3068797T3 PL 14860292 T PL14860292 T PL 14860292T PL 14860292 T PL14860292 T PL 14860292T PL 3068797 T3 PL3068797 T3 PL 3068797T3
Authority
PL
Poland
Prior art keywords
tumors
constructs
valent
targeting
valent targeting
Prior art date
Application number
PL14860292T
Other languages
English (en)
Inventor
Waldemar Debinski
Carla Lema TOMÉ
Sara FERLUGA
Poonam S. SONAWANE
Original Assignee
Wake Forest University Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University Health Sciences filed Critical Wake Forest University Health Sciences
Publication of PL3068797T3 publication Critical patent/PL3068797T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL14860292T 2013-11-11 2014-11-11 Konstrukty wielowalentnego celowania w nowotwory PL3068797T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361902568P 2013-11-11 2013-11-11
US201462036262P 2014-08-12 2014-08-12
PCT/US2014/064983 WO2015070210A1 (en) 2013-11-11 2014-11-11 Epha3 and multi-valent targeting of tumors
EP14860292.3A EP3068797B1 (en) 2013-11-11 2014-11-11 Constructs for multi-valent targeting of tumors

Publications (1)

Publication Number Publication Date
PL3068797T3 true PL3068797T3 (pl) 2020-06-29

Family

ID=53042230

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14860292T PL3068797T3 (pl) 2013-11-11 2014-11-11 Konstrukty wielowalentnego celowania w nowotwory

Country Status (5)

Country Link
US (4) US9975942B2 (pl)
EP (1) EP3068797B1 (pl)
CA (1) CA2930243A1 (pl)
PL (1) PL3068797T3 (pl)
WO (1) WO2015070210A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619334A (zh) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
US20180369422A1 (en) * 2015-12-31 2018-12-27 City Of Hope Nanoparticles for cancer detection
WO2019073299A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
CA3102097A1 (en) * 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior Unversity Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
IL291937A (en) * 2019-10-09 2022-06-01 Council Queensland Inst Medical Res Targeting epha3 and uses thereof
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN121079316A (zh) * 2023-05-02 2025-12-05 韦克福里斯特大学健康科学院 多靶药物缀合物及其用于癌症治疗的用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5328984A (en) 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6428788B1 (en) 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
DE19617851A1 (de) 1996-05-03 1997-11-13 Hoechst Ag Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
CA2227840A1 (en) 1997-01-30 1998-07-30 Masahiro Kishine Multilayer film for packaging
US6884603B2 (en) 1998-04-03 2005-04-26 The Penn State Research Foundation Nucleic acids encoding IL13 mutants
US6630576B2 (en) 1998-04-03 2003-10-07 Pennsylvania State Research Foundation Amino acid substitution mutants of interleukin 13
US6296843B1 (en) 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7078030B2 (en) 1999-11-15 2006-07-18 Onyx Pharmaceuticals, Inc Oncolytic adenovirus
US20010046498A1 (en) 2000-01-21 2001-11-29 Ruoslahti Erkki I. Chimeric prostate-homing peptides with pro-apoptotic activity
DE20009317U1 (de) 2000-05-24 2000-08-17 Arturo Salice S.P.A., Novedrate, Como Befestigungsplatte zur Befestigung eines Scharnierarmes eines Möbelscharniers
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP2005511761A (ja) 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
IL161863A0 (en) 2001-11-09 2005-11-20 Neopharm Inc Selective treatment of il-13 expressing tumors
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
DE60325184D1 (de) 2002-03-01 2009-01-22 Immunomedics Inc Rs7 antikörper
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7655413B2 (en) 2003-06-26 2010-02-02 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
JP4762904B2 (ja) 2003-11-13 2011-08-31 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン不変領域の量産方法
US20060121539A1 (en) 2004-10-21 2006-06-08 The Penn State Research Foundation Eph receptor tumor biomarkers
US7531624B2 (en) 2004-12-03 2009-05-12 Medtrain Technologies, Llc Nuclear targeting sequence
CA2638888A1 (en) 2004-12-04 2006-06-15 The Regents Of The University Of California Protein subcellular localization assays using split fluorescent proteins
US8153598B2 (en) 2005-10-19 2012-04-10 Intrexon Corporation PKD ligands and polynucleotides encoding PKD ligands
US8252338B2 (en) 2005-11-10 2012-08-28 The Regents Of The University Of California Synthetic LDL as targeted drug delivery vehicle
US8343461B2 (en) * 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
US7498177B2 (en) 2006-04-24 2009-03-03 Jesus Martinez De La Fuente Quantum dots and their uses
CN101616911A (zh) 2007-02-21 2009-12-30 梅达莱克斯公司 具有单个氨基酸的化学连接物及其偶联物
CA2679986C (en) * 2007-03-08 2018-03-06 Martin Lackmann Epha3 antibodies for the treatment of solid tumors
US8535726B2 (en) 2007-07-27 2013-09-17 The Board Of Trustees Of The Leland Stanford Junior University Supramolecular functionalization of graphitic nanoparticles for drug delivery
WO2009097017A2 (en) 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
ES2647538T3 (es) 2007-09-28 2017-12-22 Pfizer Inc. Direccionamiento a células de cáncer usando nanopartículas
EP2385854B1 (en) 2009-01-12 2014-05-21 Becton, Dickinson and Company Optimized intracranial catheters for convection-enhanced delivery of therapeutics
US9296785B2 (en) 2009-04-17 2016-03-29 Wake Forest University Health Sciences IL-13 receptor binding peptides
AU2010239216B2 (en) 2009-04-21 2012-07-12 Amgen Inc. Fragmentation resistant IgG1 Fc-conjugates
EP2253716A1 (en) 2009-05-15 2010-11-24 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Diagnostic methods for the prognosis of a brain tumor
CN102573979B (zh) 2009-08-25 2016-01-13 加利福尼亚大学董事会 用于向大脑递送治疗剂的导管优化配置
WO2011094446A1 (en) 2010-01-27 2011-08-04 Neumedicines, Inc A method for treating brain cancer using a novel tumor suppressor gene and secreted factor
US8362207B2 (en) 2010-04-16 2013-01-29 Wake Forest University Health Sciences Multi-level specific targeting of cancer cells with IL-13
CA2800497C (en) 2010-05-10 2019-03-12 The Regents Of The University Of California Methods for preparing ratiometric combinatorial nanoparticules
US20130209641A1 (en) 2012-02-03 2013-08-15 Leszek Kot Food Cooking Apparatus and Method

Also Published As

Publication number Publication date
US20230272033A1 (en) 2023-08-31
EP3068797A1 (en) 2016-09-21
EP3068797A4 (en) 2017-08-02
US10752667B2 (en) 2020-08-25
US20180244745A1 (en) 2018-08-30
US11697675B2 (en) 2023-07-11
EP3068797B1 (en) 2020-01-08
US20160297863A1 (en) 2016-10-13
US9975942B2 (en) 2018-05-22
CA2930243A1 (en) 2015-05-14
US20200347113A1 (en) 2020-11-05
WO2015070210A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
EP2954056A4 (en) NEW MULTISPECIFIC CONSTRUCTIONS
HUE071428T2 (hu) HER2-T célzó bispecifikus antigénkötõ-konstrukciók
GB201321710D0 (en) Electrosurgical apparatus
GB201308558D0 (en) Electrosurgical apparatus
GB201322725D0 (en) Cancer therapy
IL240327A0 (en) New pyrazole derivatives
PL3068797T3 (pl) Konstrukty wielowalentnego celowania w nowotwory
IL244758A0 (en) Preparation of a history of hydroxy-benzylbenzene
GB201308207D0 (en) Electrosurgical apparatus
SG11201509707QA (en) Cancer therapy
IL241109A0 (en) Targeted vaccines for veterinary use
ZA201604502B (en) Use of benzimidazole-proline derivatives
SG11201507847UA (en) Cancer therapy
GB201300289D0 (en) Head-mountable apparatus
ZA201507251B (en) Antibodies targeting m-csf
EP2961412A4 (en) CANCER THERAPY
EP2967011A4 (en) ANIMAL CANCER MODELS
GB201301125D0 (en) Methods for improving the efficency of gene targeting
GB201316666D0 (en) Targeting molecule
GB201518731D0 (en) Tumour Therapy
GB2515130B (en) Head-mountable apparatus
GB201312336D0 (en) Detection of Brain Cancer
GB201308365D0 (en) Tumour therapy
GB201317213D0 (en) Cancer Therapy
GB201310302D0 (en) Sequencer